Array biopharma to present clinical data on arry-520, a ksp inhibitor, and arry-614, a dual p38/tie2 inhibitor, at the 2011 american society of hematology annual meeting

Boulder, colo.--(business wire)--array biopharma inc. (nasdaq: arry) today announced data will be presented on two drug candidates, arry-520, a ksp inhibitor, and arry-614, a dual p38/tie2 inhibitor, at the 2011 annual meeting of the american society of hematology in san diego, california. the abstracts can be accessed through the american society of hematology website, www.hematology.org/meetings/annual-meeting. the abstract titles are provided below; however, please note that according to ash press policies, all data are embargoed until the time of the beginning of the presentation. after the presentations, the posters and presentation slides will be available as pdfs on array's website at www.arraybiopharma.com. poster: arry-520 shows durable responses in patients with relapsed/refractory multiple myeloma in a phase 1 dose-escalation study (publication #1860) date: time: location: oral presentation: phase 1 dose-escalation/expansion study of the p38/tie2 inhibitor arry-614 in patients with ipss low/int-1 risk myelodysplastic syndromes (abstract #118) presenter: date: time: location: poster: the novel ksp inhibitor arry-520 demonstrates single-agent activity in refractory myeloma: results from a phase 2 trial in patients with relapsed/refractory multiple myeloma (mm) (publication #2935) date: time: location: about array biopharma array biopharma inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. for more information on array, please go to www.arraybiopharma.com.
ARRY Ratings Summary
ARRY Quant Ranking